A Phase 2 Double-blind, Randomized, Multi-center, Parallel-group Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Patients With Acute Ischemic Stroke
Latest Information Update: 16 Jan 2024
At a glance
- Drugs TB 006 (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Sponsors TrueBinding
- 10 Jan 2024 Planned End Date changed from 1 Apr 2024 to 18 Dec 2023.
- 10 Jan 2024 Planned primary completion date changed from 1 Apr 2024 to 18 Dec 2023.
- 10 Jan 2024 Planned initiation date changed from 1 May 2023 to 26 Jul 2022.